Advertisement

Testing Genetic Modifiers of Behavior and Response to Atomoxetine in Autism Spectrum Disorder with ADHD

  • Elizabeth S. Barrie
  • Julia K. Pinsonneault
  • Wolfgang Sadee
  • Jill A. Hollway
  • Benjamin L. Handen
  • Tristram Smith
  • L. Eugene Arnold
  • Eric Butter
  • Emily Hansen-Kiss
  • Gail E. Herman
  • Michael G. Aman
ORIGINAL ARTICLE
  • 92 Downloads

Abstract

Frequent non-pathogenic genetic variants may act as moderators of phenotypic severity for complex disorders such as autism spectrum disorder (ASD). We previously identified polymorphisms affecting mRNA expression of candidate genes, including tryptophan hydroxylase 2 (TPH2), dopamine beta hydroxylase (DBH), and dopamine transporter (DAT, SLC6A3). We compare genotypes and (1) clinical response to atomoxetine, (2) scores from the Autism Diagnostic Interview-Revised (ADI-R), and (3) severity of Attention Deficit Hyperactivity Disorder (ADHD) symptoms in a cohort of patients with ASD from multiple study sites. There was no association between CYP2D6 metabolizer status and atomoxetine response. TPH2 rs7305115 genotype was associated with ADI-R Restrictive/Repetitive Behavior score (p = 0.03). DBH rs1611115 genotype was associated with ADI-R Social score (p = 0.002), and Restrictive/Repetitive Behavior score (p = 0.04). The DAT intron 8 5/6 repeat was associated with ADHD symptoms (ABC Hyperactivity p = 0.01 and SNAP ADHD p = 0.03), replicating a previous finding. We find associations between ASD phenotypes and regulatory variants in catecholamine biosynthesis genes. This work may help guide future genetics studies related to ASD.

Keywords

Autism spectrum disorder (ASD) Genetics Restrictive and repetitive behavior Atomoxetine (Strattera) Tryptophan hydroxylase 2 (TPH2Dopamine transporter (DAT SLC6A3Attention deficit/hyperactivity disorder (ADHD) 

Notes

Acknowledgements

The authors are grateful to Gloria Smith for assistance with sample preparation and to the participating families for volunteering for this research.

Compliance with Ethical Standards

Funding

This work was supported by grants from: the National Institute of General Medical Sciences (U01GM092655), Center for Clinical and Translational Science at The Ohio State University (ARRA Pilot Project UL1 RR025755 project 60023888), National Institute of Mental Health to Ohio State University (5R01MH079080), University of Pittsburgh (5R01MH079082–05), and University of Rochester (5R01 MH083247), by Eli Lilly and Co., who provided atomoxetine and placebo, the National Center for Research Resources [University of Rochester CTSA (UL1 RR024160), Ohio State University CTSA (UL1TR001070)] and the National Center for Advancing Translational Sciences of the National Institutes of Health and the United States Air Force Department of Defense (FA7014–09–2-0004 and FA8650–12–2-6359). We are grateful to all the families participating in the CORA registry. The views and opinions expressed in this article are those of the author(s) and do not reflect official policy or position of the National Institutes of Health (NIH), United State Air Force, Department of Defense, or US Government. The use of product(s) and/or manufacturer name(s) is added for clarification only; in no way implies endorsement by the authors, USAF, or DoD of the product(s) or manufacturer(s). The funders have not imposed any restrictions on free access to or publication of the research data.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

This study was approved by the institutional review boards at all sites; parents/legal guardians of all participants signed informed consent documents, and children assented if able to do so.

Conflicts of Interest

Dr. Elizabeth Barrie declares that she has no conflict of interest.

Dr. Julia K. Pinsonneault received research funding from the Center for Clinical and Translational Science at The Ohio State University.

Dr. Wolfgang Sadee received research funding from the National Institute of General Medical Sciences.

Dr. Jill Hollway has received research contracts from Forest Research Institute, Supernus Pharmaceuticals, Sunovion Pharmaceuticals, Young Living Essential Oils, and Hoffman-La-Roche.

Dr. Tristram Smith has received research funding from the National Center for Research Resources and the National Institute of Mental Health.

Dr. Benjamin Handen has received research funding from Curemark, Autism Speaks, Eli Lilly and Co., Roche and the National Institute of Mental Health.

Dr. L. Eugene Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, and YoungLiving (as well as NIH and Autism Speaks), has consulted with Gowlings, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint, been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, and received travel support from Noven.

Dr. Eric Butter has received research funding from CogState, Bracket, Autism Speaks, the Simons Foundation, and Roche.

Ms. Emily Hansen-Kiss, LGC declares that she has no conflict of interest.

Dr. Gail E. Herman has received research funding from the National Center for Advancing Translational Sciences of the National Institutes of Health and the United States Air Force Department of Defense.

Dr. Michael Aman has received research contracts, consulted with, served on advisory boards, or done investigator training for Aevi Genomic Medicine, AMO Pharma, CogState, Inc.; CogState Clinical Trials, Ltd.; Coronado Biosciences; Forest Research; Hoffman-La Roche; Johnson and Johnson; Lumos Pharma, MedAvante, Inc.; Ovid Therapeutics, ProPhase LLC; and Supernus Pharmaceuticals. He also received research funding from the National Institute of Mental Health, and the Ohio State University CTSA.

Glossary of Genetic Terms

Allele

a version of the gene, each inherited from a different parent.

Heterozygous

a genotype of two different alleles at a given SNP, also referred to as carrier.

Homozygous

a genotype where both alleles are the same at a given SNP.

Major allele

the allele that is most frequent in the general population.

Minor allele

the allele that is less frequently observed in the population.

SNP

single nucleotide polymorphism, also referred to as genetic variant.

Wild-type

homozygous for the major allele.

References

  1. AACAP Work Group on Quality Issues. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 894–921.  https://doi.org/10.1097/chi.0b013e318054e724.CrossRefGoogle Scholar
  2. Abrahams, B. S., & Geschwind, D. H. (2010). Connecting genes to brain in the autism spectrum disorders. Archives of Neurology, 67, 395–399.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Aman, M. G., & Singh, N. N. (2017). Aberrant behavior checklist manual (2nd ed.). East Aurora: Slosson Educational Publications, Inc..Google Scholar
  4. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485–491.PubMedGoogle Scholar
  5. The American Psychiatric Association (APA). (2000). Diagnostic and statistical manual of mental disorders-text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.CrossRefGoogle Scholar
  6. The American Psychiatric Association (APA). (2013). Diagnostic and statistical manual of mental disorders (5th edn.). Arlington, VA: American Psychiatric Association.Google Scholar
  7. Barrie, E. S., Weinshenker, D., Verma, A., Pendergrass, S. A., Lange, L. A., Ritchie, M. D., …Sadee, W. (2014) Regulatory polymorphisms in human DBH affect peripheral gene expression and sympathetic activity. Circulation Research 115 (12): 1017–1025.Google Scholar
  8. Bhaduri, N. & Mukhopadhyay, K. (2008). Correlation of plasma dopamine beta-hydroxylase activity with polymorphisms in DBH gene: a study on Eastern Indian population. Cell Mol Neurobiol, 28(3): 343-350.Google Scholar
  9. Bray, N. J., Buckland, P. R., Williams, N. M., Williams, H. J., Norton, N., Owen, M. J., & O'Donovan, M. C. (2013). A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. American Journal of Human Genetics, 73(1), 152–161.CrossRefGoogle Scholar
  10. Carter, A.S., Volkmar, F.R., Sparrow, S. S, … & Schopler, E. (1998). The Vineland adaptive behavior scales: Supplementary norms for individuals with autism. Journal of Autism and Developmental Disorders, 28, 287–302.Google Scholar
  11. Coon, H., Dunn, D., Lainhart, J., Miller, J., Hamil, C., Battaglia, A., … McMahon, W. (2005) Possible association between autism and variants in the brain-expressed tryptophan hydroxylase gene (TPH2). American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 135B : 42–46.Google Scholar
  12. Corsello, C. M. (2005). Early intervention in autism. Infants & Young Children, 18(2), 74–85.CrossRefGoogle Scholar
  13. Cottrell, C. E., Bir, N., Varga, E., Alvarez, C. E., Bouyain, S., Zernzach, R., … Herman, G. E. (2011) Contactin 4 as an autism susceptibility locus. Autism Research 4(3): 189–199.Google Scholar
  14. Coury, D.L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., … Perrin, J.M. (2012) Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 130 Suppl 2:S69–76.Google Scholar
  15. Eaves, L. C., & Ho, H. H. (1997). School placement and academic achievement in children with autistic spectrum disorders. Journal of Developmental and Physical Disabilities, 9, 277–291.CrossRefGoogle Scholar
  16. Egawa, J., Watanabe, Y., Nunokawa, A., Endo, T., Kaneko, N., Tamura, R., Sugiyama, T., & Someya, T. (2012). A detailed association analysis between the tryptophan hydroxylase 2 (TPH2) gene and autism spectrum disorders in a Japanese population. Psychiatry Research, 196, 320–322.CrossRefPubMedGoogle Scholar
  17. Gabriele, S., Sacco, R., & Persico, A. M. (2014). Blood serotonin levels in autism spectrum disorder: A systematic review and meta-analysis. European Neuropsychopharmacology, 24, 919–929.CrossRefPubMedGoogle Scholar
  18. Gadow, K. D., Pinsonneault, J. K., Perlman, G., & Sadee, W. (2014). Association of dopamine gene variants, emotion dysregulation and ADHD in autism spectrum disorder. Research in Developmental Disabilities, 35(7), 1658–1665.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Garland, E., Black, B., Harris, P., & Robertson D. (2007). Dopamine-beta-hydroxylase in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol, 293(1): H684-690.Google Scholar
  20. Handen, B.L., Aman, M.G., Arnold, L.E., Hyman, S.L., Tumuluru, R.V., Lecavalier, L., … Smith T.J. (2015) Atomoxetine, parent training, and their combination in children with autism Spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 54 (11):905–15.Google Scholar
  21. Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R. J., Escobar, R., Schacht, A., … Hoekstra, P. J. (2012) A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry 51(7), 733–741.Google Scholar
  22. Hérault, J., Perrot, A., Barthélémy, C., Büchler, M., Cherpi, C., Leboyer, M.,… Müh, J. P. (1993) Possible association of c-Harvey-Ras-1 (HRAS-1) marker with autism. Psychiatry Research 46(3): 261–267.Google Scholar
  23. Howlin, P., Goode, S., Hutton, J., & Rutter, M. (2004). Adult outcome for children with autism. Journal of Child Psychology and Psychiatry, 45, 212–229.CrossRefPubMedGoogle Scholar
  24. Koegel, R. L., Koegel, L. K., & McNerney, E. K. (2001). Pivotal areas in intervention for autism. Journal of Clinical Child & Adolescent Psychology, 30(1), 19–32.CrossRefGoogle Scholar
  25. Lam, K. S., Aman, M. G., & Arnold, L. E. (2006). Neurochemical correlates of autistic disorder: A review of the literature. Research in Developmental Disabilities, 27(3), 254–289.CrossRefPubMedGoogle Scholar
  26. Li, X., Zou, H., & Brown, W. T. (2012). Genes associated with autism spectrum disorder. Brain Research Bulletin, 88, 543–552.CrossRefPubMedGoogle Scholar
  27. Lim, J., Pinsonneault, J., Sadee, W., & Saffen, D. (2007). Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons. Molecular Psychiatry, 12, 491–501.CrossRefPubMedGoogle Scholar
  28. Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24, 659–685.CrossRefPubMedGoogle Scholar
  29. Miles, J.H. (2011). Autism spectrum disorders--a genetics review. Genet Med, 13, 278-294.Google Scholar
  30. Mossner, R., Walitza, S., Geller, F., Scherag, A., Gutknecht, L., Jacob, C., …, Lesch, K.P. (2006) Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacology 9 : 437–442.Google Scholar
  31. Moyer, R. A., Wang, D., Papp, A. C., Smith, R. M., Duque, L., Mash, D. C., & Sadee, W. (2011). Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. Neuropsychopharmacology, 36(4), 753–762.CrossRefPubMedGoogle Scholar
  32. Muller, C. L., Anacker, A. M., & Veenstra-VanderWeele, J. (2016). The serotonin system in autism spectrum disorder: From biomarker to animal models. Neuroscience, 321, 24–41.CrossRefPubMedGoogle Scholar
  33. Mustapic, M., Pivac, N., Kozaric-Kovacic, D., Dezeljin, M., Cubells, J.F. & Mück-Seler D. (2007). Dopamine beta-hydroxylase (DBH) activity and 1021C/T polymorphism of DBH gene in combat-related post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet, 144B(8): 1087-1089.Google Scholar
  34. Papp, A. C., Pinsonneault, J. K., Cooke, G., & Sadée, W. (2003). Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves. BioTechniques, 34(5), 1068–1072.PubMedGoogle Scholar
  35. Pinsonneault, J. K., Han, D. D., Burdick, K. E., Kataki, M., Bertolino, A., Malhotra, A. K., Gu, H. H., & Sadee, W. (2011). Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology, 36, 1644–1655.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Ramoz, N., Cai, G., Reichert, J.G., Corwin, T.E., Kryzak, L.A., Smith, C.J., … Buxbaum, J.D. (2006) Family-based association study of TPH1 and TPH2 polymorphisms in autism. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 141B : 861–867.Google Scholar
  37. Retz, W., Rösler, M., Kissling, C., Wiemann, S., Hünnerkopf, R., Coogan, A., Thome, J., & Freitag, C. (2008). Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. J Neural Transm (Vienna), 115(2), 323–329.CrossRefGoogle Scholar
  38. Robinson, P. D., Schutz, C. K., Macciardi, F., White, B. N., & Holden, J. J. (2001). Genetically determined low maternal serum dopamine beta-hydroxylase levels and the etiology of autism spectrum disorders. American Journal of Medical Genetics, 100(1), 30–36.CrossRefPubMedGoogle Scholar
  39. Rommelse, N. N., Franke, B., Geurts, H. M., Hartman, C. A., & Buitelaar, J. K. (2010). Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. European Child & Adolescent Psychiatry, 19(3), 281–295.CrossRefGoogle Scholar
  40. Ruble, C. L., Smith, R. M., Calley, J., Munsie, L., Airey, D. C., Gao, Y., et al. (2016). Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: Identification of novel HTR2A and antisense (HTR2A-AS1) exons. BMC Genetics, 17, 16.CrossRefPubMedPubMedCentralGoogle Scholar
  41. Sacco, R., Papaleo, V., Hager, J., Rousseau, F., Moessner, R., Militerni, R., … Persico, A.M. (2007) Case-control and family-based association studies of candidate genes in autistic disorder and its endophenotypes: TPH2 and GLO1. BMC Medical Genetics 8: 11.Google Scholar
  42. Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008). Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child & Adolescent Psychiatry, 47, 921–929.CrossRefGoogle Scholar
  43. Singh, A. S., Chandra, R., Guhathakurta, S., Sinha, S., Chatterjee, A., Ahmed, S., Ghosh, S., & Rajamma, U. (2013). Genetic association and gene-gene interaction analyses suggest likely involvement of ITGB3 and TPH2 with autism spectrum disorder (ASD) in the Indian population. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 45, 131–143.CrossRefGoogle Scholar
  44. Smith, R. M., Banks, W., Hansen, E., Sadee, W., & Herman, G. E. (2014). Family-based clinical associations and functional characterization of the serotonin 2A receptor gene (HTR2A) in autism Spectrum disorder. Autism Research, 7(4), 459–467.CrossRefPubMedPubMedCentralGoogle Scholar
  45. Tassone, F., Qi, L., Zhang, W., Hansen, R. L., Pessah, I. N., & Hertz-Picciotto, I. (2011). MAOA, DBH, and SLC6A4 variants in CHARGE: A case-control study of autism spectrum disorders. Autism Research, 4(4), 250–261.CrossRefPubMedPubMedCentralGoogle Scholar
  46. Virués-Ortega, J. (2010). Applied behavior analytic intervention for autism in early childhood: Meta-analysis, meta-regression and dose–response meta-analysis of multiple outcomes. Clinical Psychology Review, 30, 387–399.  https://doi.org/10.1016/j.cpr.2010.01.008.CrossRefPubMedGoogle Scholar
  47. Warren, Z., McPheeters, M.L., Sathe, N., Foss-Feig, J.H., Glasser, A., & Veenstra-VanderWeele, J. (2011). A systematic review of early intensive intervention for autism spectrum disorders. Pediatrics, 127, e1303–e1311.Google Scholar
  48. World Health Organization (WHO). (1996). ICD-9-CM: International classification of diseases, 9th revision, clinical modification. Salt Lake City: Medicode.Google Scholar
  49. Yang, S. Y., Yoo, H. J., Cho, I. H., Park, M., & Kim, S. A. (2012). Association with tryptophan hydroxylase 2 gene polymorphisms and autism spectrum disorders in Korean families. Neuroscience Research, 73, 333–336.CrossRefPubMedGoogle Scholar
  50. Zabetian, C. P., Anderson, G. M., Buxbaum, S. G., Elston, R. C., Ichinose, H., Nagatsu, T., Kim, K. S., Kim, C. H., Malison, R. T., Gelernter, J., & Cubells, J. F. (2001). A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: Evidence for a major functional polymorphism at the DBH locus. American Journal of Human Genetics, 68(2), 515–522.CrossRefPubMedPubMedCentralGoogle Scholar
  51. Zhang, Y., Bertolino, A., Fazio, L., Blasi, G., Rampino, A., Romano, R., … Sadée, W. (2007) Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proceedings of the National Academy of Sciences of the United States of America 104, 20552–20557.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Elizabeth S. Barrie
    • 1
    • 2
  • Julia K. Pinsonneault
    • 1
  • Wolfgang Sadee
    • 1
  • Jill A. Hollway
    • 1
  • Benjamin L. Handen
    • 3
  • Tristram Smith
    • 4
  • L. Eugene Arnold
    • 1
  • Eric Butter
    • 1
    • 5
  • Emily Hansen-Kiss
    • 2
  • Gail E. Herman
    • 1
    • 2
  • Michael G. Aman
    • 1
    • 6
  1. 1.The Ohio State UniversityColumbusUSA
  2. 2.Institute for Genomic MedicineNationwide Children’s HospitalColumbusUSA
  3. 3.Departments of Psychiatry and PediatricsUniversity of Pittsburgh School of MedicinePittsburghUSA
  4. 4.Department of PediatricsUniversity of Rochester Medical CenterRochesterUSA
  5. 5.Department of PsychologyNationwide Children’s HospitalColumbusUSA
  6. 6.The Nisonger Center UCEDDOhio State UniversityColumbusUSA

Personalised recommendations